Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


Therapeutic Targeting Agents for Bladder Cancer

Funder: National Cancer Institute

Funding period
USD 266 K
Funding amount
DESCRIPTION (provided by applicant): The purpose of this project is to develop novel cell-selective therapeutic targeting agents for treating bladder cancer. Making use of two non-overlapping phage-display derived bladder cancer-specific binding peptides (BCSBPs) already developed, conjugates will be created between these BCSBPs and both an active chemotherapeutic drug (Epirubicin) and two biologic proteins (cytokines IL-2 and IL-12). Binding and functional activity of these BCSBPs will be optimized against a mouse bladder cancer cell line previously shown to share the same binding characteristics for these BCSBPs as multiple human bladder cancer cell lines. The long-term goal is to develop the necessary methodology for translating these targeting motifs into clinical use immunotherapeutic against human bladder cancer. Towards achieving these goals, two specific aims will be undertaken: Specific Aim 1: To chemically conjugate BCSBPs with the chemotherapeutic drug Epirubicin, and to assess cytotoxicity of the conjugates in targeting bladder cancer cells. The conjugates will be made through a chemical coupling process that explores positional effects, number of targeting motifs and use of spacers to achieve maximal binding specificity, affinity, and functional cytotoxic activity. Specific aim 2: To genetically conjugate BCSBPs with Thl cytokines IL-2 and IL-12, and to assess the binding and biological activities of these fusion proteins upon targeted bladder cancer cells. These fusion proteins will be made using prokaryotic or insect expression systems. Binding specificity will be optimized using a GFP-conjugate prototype. Biological activity for IL-2 and IL-12, alone and as synergistic agents will be tested using well-established bioassays. Successful completion of this study will result in future pre-clinical studies using these novel therapeutic conjugates in animal bladder cancer models that may further lead to a quick translation of this strategy into a clinically useful treatment modality for human bladder cancer.
Similar projects All >
Sorted by: Start Date
Project list item
Characterization of Nectin-4 expression in molecular subtypes of urothelial cancer and mechanisms of resistance to enfortumab vedotin

Bladder Cancer Advocacy Network to Carissa Ellen Chu

USD 1,700
2020 - 2020
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer


USD 703,400
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Chimeric RNAs and their implication in lymphatic metastasis of bladder cancer

National Cancer Institute to HUI LI

USD 205,913
2020 - 2025



    1112 Oncology and Carcinogenesis

  • RCDC


  • RCDC


  • RCDC

    Urologic Diseases




    5.1 Pharmaceuticals

  • Health Research Areas


  • Broad Research Areas

    Basic Science